Biointron Weekly Reports

News?

Together with the Chinese Antibody Society , our latest webinar features Shun Zhou , Ph.D, the R&D Director at Cyagen : “Accelerating Antibody Discovery with Fully Human Antibody Mouse HUGO-Ab? and Single B Cell Screening Technology AbDrop?”?

Watch it now on YouTube! ???? https://www.youtube.com/watch?v=CxozT9LEu58 ?

If you haven’t had a chance to review our latest Antibody Industry Q3 report , there’s still time to take a look now. Dive into the latest trends, breakthroughs, and insights shaping the antibody industry. Gain exclusive insights into:?

• ?? Five novel antibody drugs approved for the first time in Q3?

• ?? Top 10 antibody drug deals, including collaborations, M&As, and funding rounds of up to $3B?

• ?? A focus on hot antibody startups launching with up to $370M in funding?

• ?? Trends in higher drug-antibody ratios for antibody-drug conjugates (ADCs)?

• ?? Positive updates on anti-TIGIT therapies?

• ?? A list of antibody drugs in regulatory review to keep an eye out for in Q4?

Download the full report for free here.

?

This Week’s News

• Detection of host cell microprotein impurities in antibody drug products

• A novel bispecific CD40 agonistic antibody allowing for antibody-peptide conjugate formation to enable cancer-specific peptide delivery

• Webinar : Accelerating Antibody Discovery with Fully Human Antibody Mouse HUGO-Ab? and Single B Cell Screening Technology AbDrop?

?

Trends – Infant RSV?

Respiratory Syncytial Virus (RSV) is a leading cause of severe respiratory infections, particularly in infants, the elderly, and immunocompromised individuals. Despite its global prevalence, there has historically been a lack of effective therapeutic options for high-risk populations. Advances in antibody drug discovery have paved the way for innovative treatments, offering targeted approaches to neutralize RSV. Monoclonal antibodies, with their ability to bind specifically to the RSV fusion (F) protein, are transforming how we prevent and manage this virus. Here we highlight recent research advances.?

Researchers from Fred Hutch Cancer Center have developed a new anti-idiotype antibody as a first step in possible strategy to build infant immunity during their vulnerable window.?Antibodies derived from VH3-21/VL1-40 gene paring are hardwired to neutralize RSV?without the need for affinity maturation, making them attractive to target through vaccination. Here, they develop a bispecific anti-idiotypic antibody (ai-mAb ) to target VH3-21/VL1-40 B cell receptors (BCRs). The ai-mAb efficiently engages B cells?encoding RSV-neutralizing antibodies. These results establish proof of concept for using an ai-mAb-derived vaccine to target B cells hardwired to produce RSV-neutralizing antibodies.

Meanwhile, a recent study reveals that maternal RSV vaccination timing is key to safeguarding newborns, with vaccination early in the approved window (≥ 5 weeks prior to delivery) allowing for the most efficient placental transfer of maternal antibody. This analysis adds needed data about transplacental antibody transfer efficiency week-by-week after maternal RSV vaccination, suggesting that clinical guidance for vaccination timing within the approved window may need to be refined to optimize neonatal protection.?

In exciting news, Merck Group ’s RSV shot for infants (Clesrovimab ) showed promise from Phase 2b/3 trial results?and could be available in 2025. Clesrovimab is an investigational RSV preventative extended half-life?monoclonal antibody that was 91% effective at preventing medically attended lower respiratory tract infections vs. Placebo. It is designed to be administered as the same single dose, regardless of birth weight. One dose of clesrovimab performed similarly to five doses of palivizumab among high-risk infants.

?

Upcoming Events?

Next month, we will be exhibiting at three conferences!?

1. The 3rd Annual Meeting of the Antibody Society of Japan will be held on December 9-11, 2024, at Sendai International Center in Sendai, Japan. Find us at Booth #39! ?
2. Chinese Antibody Society's 2024 mAbTalk Symposium, themed "AntibodyPlus - Bispecific Antibodies and Antibody-Drug Conjugates." This event will be on December 15, 2024, at?Hilton San Diego Bayfront, San Diego, CA.?
3. On December 15-18, 2024, Biointron will also be at the Antibody Engineering & Therapeutics US. The event will be held at the Marriott Marquis San Diego, San Diego, CA. Meet us at Booth #109! ?

Promotions – 40% OFF Abinvivo Products! ???

Explore Abinvivo, our brand for ???????????????????? ?????? ???? ???????? ????????????????! ?? Save on your project with our ????????-?????????????? ???????????????? - 40% off sitewide! Now with online checkout and 1 week delivery:?

?? https://www.abinvivo.com/abinvivo/Home ?

• ? ?????????????????? ???????????????? ?????????????????

• ?? ?????????????? ???????????????? ?????????????????

• ?? ????????-?????????? ?????????????????

• ? ???????????????????? ?????????????????

• ...and more!

RushMab - Gene? is your go-to solution for quick plasmid production, designed specifically for antibody-related research. We offer a 4-day turnaround, delivering high-quality, transfection-grade expression plasmids for IgG, Fab, VHH, and ScFv sequences. We provide quantities of 100 μg (sufficient for 100 ml culture) with scalability up to grams. Using the reliable pcDNA3.4 backbone, we also accommodate custom vectors. Each plasmid undergoes Sanger sequencing verification and endotoxin control, ensuring precision and safety.

?

New Products & Reports?

• Q3 2024 Antibody Industry Report is out now! ?

• Fully Human Antibody Mouse HUGO-Ab? and High-Throughput Single B Cell Screening AbDrop? ?

• Small-Scale Packages-RushMab?: Purified Antibodies in 4-10 Days! ?

• CHOK1-FUT8 Afucosylated Antibody Expression Platform ?

?

Learn more about Biointron at www.biointron.com , or contact us at [email protected] and +1 (732) 790-8340